General MedicationsIONTOPHORESIS, TOPICALGeneric

LIDOSITE TOPICAL SYSTEM KIT

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

Standard Dose

1.05MG/PATCH;100MG/PATCH

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview LIDOSITE TOPICAL SYSTEM KIT is listed in Drugs@FDA under application 021504 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient EPINEPHRINE; LIDOCAINE HYDROCHLORIDE Form and strength PATCH;IONTOPHORESIS, TOPICAL - 1.05MG/PATCH;100MG/PATCH Sponsor VYTERIS Submission history Latest submission status date: 2005-06-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview LIDOSITE TOPICAL SYSTEM KIT is listed in Drugs@FDA under application 021504 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient EPINEPHRINE; LIDOCAINE HYDROCHLORIDE Form and strength PATCH;IONTOPHORESIS, TOPICAL - 1.05MG/PATCH;100MG/PATCH Sponsor VYTERIS Submission history Latest submission status date: 2005-06-15 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.